Navigation Links
Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference

RICHMOND, Calif., Aug. 30, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 6, 2012, at the Stifel Nicolaus Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
3. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
4. Sangamo BioSciences Reports First Quarter 2012 Financial Results
5. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Neurocrine Biosciences Reports Second Quarter 2012 Results
10. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
11. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Post Your Comments:
(Date:11/30/2015)... ... , ... Global Stem Cells Group Chile CEO ... America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology and ... will present and discuss new trends in anti-aging stem cell treatments, regenerative medicine ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group announced the opening of a new ... Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in ... and techniques in stem cell medicine to patients from around the world. , The clinics ...
(Date:11/30/2015)... 1, 2015 Partnership includes an ... for the u niversity , s ... treatment s cale - up ... Africa , where licensees based anywhere in the world will ... technology. --> Africa , where licensees based anywhere in the ...
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):